Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Denileukin is an immunotherapy and targeted toxin approved by the U.S. FDA in August 2024 to treat relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults after at least one prior systemic therapy. It combines interleukin-2 (IL-2) with diphtheria toxin to kill malignant T-cells.
Denileukin is an immunotherapy and targeted toxin approved by the U.S. FDA in August 2024 to treat relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults after at least one prior systemic therapy. It combines interleukin-2 (IL-2) with diphtheria toxin to kill malignant T-cells.